The Bio Report

The growing problem of bacterial resistance to antibiotics represents a significant public health threat. That’s been made worse by the dearth of new therapies that have come to market. AmpliPhi Biosciences is developing bacteriophages, viruses that infect and kill bacteria, to provide a way to target drug-resistant bugs. We spoke to Paul Grint, CEO of AmpliPhi about the health need, AmpliPhi’s approach, and why harnessing these natural killers of bacteria may provide a promising source of new therapeutics.